Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) reviewed 2025 progress, highlighting clinical and intellectual property advances for its lead candidate CMND-100, an oral non-hallucinogenic MEAI-based therapy for Alcohol Use Disorder (AUD).

Key 2025 points: first-in-human dosing and completed enrollment/treatment for cohort 1, completed dosing for cohort 2, DSMB unanimous approval to continue after interim safety review, multinational site activations at Yale, Johns Hopkins and Israeli centers, and multiple international patent filings across neuroplastogen indications.

Positive

• First-in-human dosing completed for cohort 1
• Enrollment and dosing completed for cohort 2
• DSMB gave unanimous approval to continue after interim safety review
• Multinational site activations at Yale, Johns Hopkins, and Israeli centers

Negative

• No efficacy or pivotal clinical readouts reported yet
• No financial metrics, guidance, or timelines for pivotal trials provided

Market Reality Check

$2.29 Last Close

Volume Volume 85,021 is below the 20-day average of 518,351, indicating muted trading activity into this update. low

Technical Shares at $2.43 are trading well below the $34.61 200-day moving average and near the $2.36 52-week low, far from the $87.20 52-week high.

Peers on Argus

CMND declined 6.18% while several biotech peers were mixed: SXTP (-5.36%), TTNP (-3.96%), PLRZ (-1.9%), SILO (-6.43%), and KTTA (+0.87%). This points to a largely stock-specific move rather than a coordinated sector reaction.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Clinical trial update	Positive	-3.7%	Completion of second cohort enrollment in FDA-approved Phase I/IIa CMND-100 trial.
Dec 12	Scientific review	Positive	+3.6%	Peer-reviewed article highlighting MEAI’s potential and favorable safety profile for AUD.
Dec 12	Nasdaq compliance	Positive	+3.6%	Announcement of regaining compliance with Nasdaq minimum stockholders’ equity rule.
Dec 10	Reverse share split	Negative	-6.1%	1-for-40 reverse split to address Nasdaq minimum bid price listing requirement.
Dec 05	Listing deficiency notice	Negative	+2.5%	Nasdaq notice for noncompliance with $1.00 minimum bid price requirement.

Pattern Detected

Recent news tends to see mixed reactions: regulatory and clinical milestones often align with price moves, but some positive clinical updates have coincided with declines, while negative compliance headlines have occasionally seen upside.

Recent Company History

Over the last weeks, Clearmind reported multiple developments around CMND-100 and its Nasdaq listing. In early December 2025 it received a Nasdaq minimum bid deficiency notice, followed by a 1-for-40 reverse split to address listing issues. The company then reported regaining compliance with Nasdaq’s stockholders’ equity rule and highlighted MEAI in a peer‑reviewed review. Most recently, Clearmind announced second cohort enrollment completion in its FDA‑approved Phase I/IIa trial. Today’s year‑in‑review news reiterates these clinical and regulatory milestones in a consolidated narrative.

Market Pulse Summary

The stock is surging +10.5% following this news. A strong positive reaction aligns with Clearmind’s emphasis on progress across its FDA-approved Phase I/IIa trial and the independent DSMB safety endorsement. The update consolidates prior milestones such as first‑in‑human dosing, positive top‑line safety and tolerability, and global site activations. However, the stock’s position near its 52-week low and well below the 200-day MA underscores prior dilution and listing challenges that could temper the durability of any outsized upside move.

Key Terms

alcohol use disorder medical

"for the treatment of Alcohol Use Disorder (AUD)"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

data and safety monitoring board medical

"Received unanimous approval from the Data and Safety Monitoring Board (DSMB)"

An independent panel of experts that watches over a clinical trial to protect participants and ensure the data are reliable, acting like an impartial referee who can recommend pausing or stopping the study if safety problems or clear benefits emerge. Investors care because the board’s findings can change a drug or device’s timeline, cost, and odds of regulatory approval, directly affecting a company’s value and risk profile.

intellectual property technical

"Strengthened intellectual property portfolio and pipeline of its non-hallucinogenic neuroplastogen patents"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

ptsd medical

"targeting indications such as weight loss, obesity, metabolic disorders, depression, PTSD, anxiety"

PTSD, or post-traumatic stress disorder, is a mental health condition that can develop after experiencing or witnessing a traumatic event, leading to ongoing feelings of fear, anxiety, or distress. For investors, understanding PTSD is important because widespread psychological impacts can influence market behavior, cause sudden shifts in confidence, or affect economic stability during times of collective trauma or crisis.

AI-generated analysis. Not financial advice.

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD).

Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options.

Key 2025 highlights include:

Clinical Trial Progress: Advanced the multinational Phase I/IIa trial with site activations at prestigious institutions, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The Company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events. Additionally, the first patients in the Israeli sites were enrolled and successfully dosed. Moreover, Clearmind completed enrollment and dosing for the second cohort, accelerating the path toward further data readouts.

Independent Safety Endorsement: Received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile.

Global Footprint Expansion: Strengthened intellectual property portfolio and pipeline  of its non-hallucinogenic neuroplastogen patents with multiple international patent filings and publications targeting indications such as weight loss, obesity, metabolic disorders, depression, PTSD, anxiety and binge behaviors.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “2025 has been a pivotal year for Clearmind as we transitioned into a clinical-stage company, executing on our multinational trial. These achievements underscore our disciplined approach to innovation and our commitment to delivering transformative treatments for addictions and mental health challenges. We are grateful to our dedicated team, clinical partners, investigators, and investors for their unwavering support.”

"Looking ahead to 2026, Clearmind remains focused on advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impact".

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder, its commitment to delivering transformative treatments for addictions and mental health challenges, advancing its pipeline, generating additional clinical data, and exploring strategic opportunities to maximize shareholder value and patient impac . Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What clinical progress did Clearmind (CMND) report for CMND-100 in 2025?

Clearmind reported first-in-human dosing, completed cohort 1 treatment, completed dosing for cohort 2, and DSMB unanimous approval to continue the Phase I/IIa trial.

Which sites are running Clearmind's Phase I/IIa CMND-100 trial (CMND) in 2025?

Activated multinational sites include Yale School of Medicine, Johns Hopkins School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

Did the Data and Safety Monitoring Board clear Clearmind's (CMND) CMND-100 trial after interim review?

Yes, the DSMB gave unanimous approval to continue the Phase I/IIa trial following an interim safety review.

Has Clearmind (CMND) reported safety issues or serious adverse events for CMND-100 in 2025?

No serious adverse events were reported in the top-line safety and tolerability results disclosed for the trial cohorts.

What intellectual property actions did Clearmind (CMND) take in 2025?

The company expanded its IP portfolio with multiple international patent filings and publications covering non-hallucinogenic neuroplastogen indications.

When should investors expect efficacy data or next CMND-100 readouts from Clearmind (CMND)?

The announcement does not provide specific timelines for efficacy or next readouts; additional clinical data are planned for 2026.